NBOMe-LAD

NBOMe-LAD, also known as LSD-NBOMe, is a receptor modulator and putative psychedelic drug of the lysergamide family related to lysergic acid diethylamide. It is the N-(2-methoxybenzyl) derivative of LSD.

Pharmacology

NBOMe-LAD is known to act as an agonist of the serotonin 5-HT_2A receptor and to interact with other receptors, but shows dramatically reduced potency compared to LSD in vitro. At the serotonin 5-HT_2A receptor, it had 37-fold lower affinity, 148-fold lower activational potency in terms of calcium release, and around half the maximal efficacy in terms of calcium release relative to LSD. On the other hand, NBOMe-LAD had only about 4-fold lower potency in terms of β-arrestin recruitment along with similar activational efficacy for this pathway relative to LSD.
NBOMe-LAD produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, but with greatly reduced potency and maximal efficacy relative to PRO-LAD and analogues. Its for inducing the head-twitch response was 13-fold lower than that of PRO-LAD and its maximal effect was about one-third that of PRO-LAD. However, the most efficacious dose of NBOMe-LAD was 3.2mg/kg whereas that of PRO-LAD was 1mg/kg.

NBOMe-LAD showed much faster metabolism than LSD in human and rat liver microsomes in vitro.

NBOMe-LAD was first described in the literature by 2022. It was described in a patent by Andrew Kruegel and Gilgamesh Pharmaceuticals. Various other NBOMe-type analogues of LSD and related compounds were also described.